Ultragenyx Pharmaceutical Inc.

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
40.88 ^USD	+1.67%		-0.54%	-14.51%

14/06	Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating	MT
14/06	Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	MT

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for 2021 and 2025

January 15, 2020 at 01:30 am IST

Ultragenyx Pharmaceutical Inc. provided 2021, 2025, company expect to get to 10x growth, be $1 billion -- have a $1 billion in revenue.

Latest news about Ultragenyx Pharmaceutical Inc.

Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating	14/06	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	14/06	MT
Ultragenyx Pharmaceutical Prices $350 Million Offering	14/06	MT
Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	13/06	MT
Ultragenyx Pharmaceutical Launches Equity Offering	13/06	MT
Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment	13/06	DJ
Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA	13/06	CI
Sector Update: Health Care Stocks Ease Late Afternoon	13/06	MT
Sector Update: Health Care	13/06	MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate	12/06	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	12/06	MT
Sector Update: Health Care	12/06	MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study	12/06	CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate	12/06	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM	11/06
Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56	06/06	MT
Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating	31/05	MT
Stifel Adjusts Price Target on Ultragenyx Pharmaceutical to $127 From $124, Maintains Buy Rating	31/05	MT
Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating	31/05	MT
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating	31/05	MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	31/05
Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia	31/05	CI
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	15/05	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM	15/05
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating	03/05	MT

Chart Ultragenyx Pharmaceutical Inc.

Duration

Period

More charts

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.88 USD

Average target price

89.95 USD

Spread / Average Target

+120.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ULTRAGENYX PHARMACEUTICAL INC.	-14.51%	3.7B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs